Visit our new Alternative Investment section.Click here
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: ripley94, 28 May 2022 12:44
Last post: ripley94, 51 mins ago
Https://www.google.com/finance/beta/quote/BNGO:NASDAQ
BioNano Genomics rose modestly following Q1 2026 results that hit the top of guidance ranges. Increased reimbursement rates for optical genome mapping serve as primary catalysts. Analysts project continued revenue growth next quarter, though sentiment suggests caution regarding the company's timeline for reaching cash flow breakeven.
..............................................................................................................................................
During the May 2026 earnings call, management explicitly stated they no longer expect to reach cash flow breakeven by the end of 2026, pushing the target to Q4 2027. This delay raises concerns regarding long-term financial sustainability and the potential need for further capital raises.
Share Price..$1.185..-0.08..(-6.69%)
Topped up again **$1.19**
USA Tec 100 was down 2.3 %.
Used brokers special loan arrangement .
As can close anytime and not just at months end .
Share Price $1.2445..-0.22..(-15.34%)
Big fall this Friday night .
Can not see any bad news.
https://www.marketbeat.com/stocks/NASDAQ/BNGO/
https://www.barchart.com/stocks/quotes/BNGO/overview
Toped up again at $1.5
.......................................................................................................................................................................
On 13 Nov 2025 Deleted an order for $1.5 , which might of executed as chart shows $1.47 at close .
Ran out of spare funds as USA 100 tec down 2.04%.
Six other buys executed .
................................................................................................................................................................
Robinhood Markets. ( Twice )
Jasper Therapeutics Inc
XTI Aerospace Inc
VolitionRX Ltd
Humacyte Inc
Earlyier on 13/11/25
McGraw Hill Inc ( Sold )
Wishbone Gold PLC
Priced on 16th September 2025
BNGO Bionano Genomics, Inc. NASDAQ Capital 2.00 4,925,000 9/16/2025 $9,850,000 Priced .
High just after at just $2.12... falling to $1.47... bouncing back to $1.85 .
https://www.barchart.com/stocks/quotes/BNGO/overview
3rd Resistance Point 1.7017
2nd Resistance Point 1.6633
1st Resistance Point 1.6267
Last Price 1.5400
1st Support Level 1.5517
2nd Support Level 1.5133
3rd Support Level 1.4767
https://www.marketbeat.com/stocks/NASDAQ/BNGO/
There are 40 funds or institutions reporting positions in Bionano Genomics. This is an increase of 2 owner(s) or 5.26% in the last quarter. Average portfolio weight of all funds dedicated to BNGO is 0.00%, an increase of 98.78%. Total shares owned by institutions increased in the last three months by 67.93% to 244K shares.
24th November 2025 HC Wainwright & Co. Maintains Bionano Genomics (BNGO) Buy Recommendation
Started: ripley94, 8 Oct 2025 19:42
Last post: ripley94, 56 mins ago
Https://www.google.com/finance/beta/quote/MBX:NASDAQ
MBX Biosciences declined approximately 21% recently despite positive clinical data and an earnings beat. Primary catalysts include encouraging Phase 1 obesity data and a strengthened cash position. Sentiment suggests a positive next quarter as analysts project upside potential following target price hikes from Barclays and Stifel.
MBX
Share Price..$40.22..+0.84..(+2.13%)
Topped out at $43.14 on 14th & 20th January .
Low since $35
Never did see it in Priced list or withdrawn .
11/06/2025 ( 6th November )$400,000,000 under Filings.MBX BIOSCIENCES INC.
As posted last month .
MBX.
Share Price $36.66..-0.37..(-0.99%)
Never did come back below $25 for a rebuy .
The 5th Feb low was $36.05.
https://robinhood.com/us/en/stocks/MBX/
Even better now at $36 year high .
3rd Resistance Point 43.02
2nd Resistance Point 39.76
1st Resistance Point 38.11
Last Price 36.00
1st Support Level 33.20
2nd Support Level 29.94
3rd Support Level 28.29
Can not see the fixed price or Withdrawn , of the other Secondary Public Offerings (SPOs) USA.
11/06/2025 ( 6th November )$400,000,000 under Filings.MBX BIOSCIENCES INC
No news of it on these two sites , but lots of upgrades on marketbeat .
Claims it will double from here .
https://www.marketbeat.com/stocks/NASDAQ/MBX/
https://www.barchart.com/stocks/quotes/MBX/overview
6th November . The day I sold for $25.15 on news of another Secondary Public Offerings (SPOs) USA.. Filings.
It continued going up after by 28th November the top out $34.5 .( 37% extra )
Still around that price today .
My first buy at 15.8 selling at 22.11 & 25.15 ( average 23.63 ) was gain of approx 50%
Apparently not necessarily a bad signal !!
Https://www.nasdaq.com/market-activity/spos
MBX BIOSCIENCES INC. 11/06/2025 ( 6th November )$400,000,000 under Filings.
Be interesting when they fix the price .
Started: ripley94, 10 Oct 2025 16:58
Last post: ripley94, 1 hour ago
Https://www.google.com/finance/beta/quote/XTIA:NASDAQ
XTI Aerospace declined approximately 10% over the past month, pressured by technical bearishness despite a significant Q1 earnings beat. Analysts project a potential rebound toward $1.80 as sentiment suggests investors are weighing optimistic 2026 revenue guidance against current cash burn and warrant-related net losses.
Share Price.$2.0103..+0.02...(+1.02%)
Sold for **2.03** the first of the two rebuys 3rd February.
Out again .
Irian war started Saturday might of helped todays rise this Monday .
Share Price.$1.86..+0.04..(+2.19%)
Sold for **1.85** one of the two rebuys last week 3rd & 5th .
Same order failed yesterday .
https://robinhood.com/us/en/stocks/XTIA/
Share Price.$ 1.580.00(0.00%)
Got some more today **$1.55 ** on big falls on many of these picks.
The low 1.51 pulled back up after 5.30pm .
Share Price..$ 1.64 .
Bought back in again for $1.63.
Has been the best so far of this bunch .
https://www.nasdaq.com/market-activity/spos
The Profit has reappeared from previous deals , but the bep now shows at the 1.63.
Total Profit and Loss (P/L):The Total Profit and Loss (P/L) is a financial result that summarizes the total income and total expenses (realized and unrealized) of the trading activity so far.
Started: ripley94, 13 Jan 2026 18:33
Last post: ripley94, 1 hour ago
Https://www.google.com/finance/beta/quote/ACTU:NASDAQ
Actuate Therapeutics declined recently despite obtaining FDA clearance for a new oral cancer trial. Analysts project that while technical trends appear bearish in the short term, clinical progress and upcoming data for elraglusib suggest a positive long-term consensus forecast for the next quarter.
.....................................................................................................................................................................................................
Despite recent price volatility, major analysts maintain 'Strong Buy' or 'Buy' ratings with price targets reaching up to $15.00. This reflects significant confidence in the company's oncology pipeline and the potential value of its Pediatric Priority Review Vouchers, which have historically traded for over $150 million.
Closed ..$2.97...+0.44...(+17.39%)
Took another slice at $2.815 ( on a $2.78 order limit ) executing strait away , the high at 6.30pm by 7.30pm up to$3.09 , very near the 3.1 seen on Monday 20th.
Fell back to 2.27 on Tuesday 21st .
https://robinhood.com/us/en/stocks/ACTU/
$2.62...+0.31...(+13.42%)
Saw these were up 28% at 3.30pm to $3.1 before falling back .
https://robinhood.com/us/en/stocks/ACTU/
$2.15..+0.07..(+3.36%)
Took a slice at $2.52 day high ten mins after at $2.59 but then dropped back , unlike the other 3 USA sales today .
4.30pm ..$1.8501..-0.25...(-11.90%)
Topped up again $ 1.81.. strait through on $1.83 order .
6th Buy .
https://www.marketbeat.com/stocks/NASDAQ/ACTU/
https://robinhood.com/us/en/stocks/ACTU/
Among the first of these picks .
Https://www.nasdaq.com/market-activity/spos
Https://www.google.com/finance/beta/quote/BIVI:NASDAQ
BioVie declined approximately 8% recently as immediate enthusiasm for trial completion met long-term solvency fears. Catalysts include the May 18 conclusion of Phase 2 Parkinson's evaluations and a Q3 earnings beat. Sentiment suggests cautious optimism for upcoming topline data, though analysts project significant risk due to limited cash runways.
...........................................................................................................
Substantial Going Concern Risks: Management has expressed significant doubt regarding the company's ability to continue operations without additional financing. Despite a recent capital raise, BioVie holds an accumulated deficit of approximately $363.3 million and requires further funding to support its extensive neurodegenerative and liver disease clinical programs.
Closed $1.31...-0.01...(-0.75%)
Another buy 1.28~ Strait through on 1.29 order .
4th May
BioVie CEO Cuong Do joined Steve Darling from Proactive Might be why I got the sale next day .
https://finance.yahoo.com/video/biovie-advances-long-covid-trial-152456713.html
No consensus
Just the one Analysts' Recommendation and its a sell .
20/4/26 Weiss Ratings...Not Rated
Bought for 1.44 today .
Another 3 in a row since the 1/5/26 Sell 1.7 this day week .
Higher then the 3 pre Christmas buys at 1.25, 1.30 & 1.4 .
30/12/25 buy for $1.145 ( sold back last Friday )
Https://robinhood.com/us/en/stocks/BIVI/
https://www.marketbeat.com/stocks/NASDAQ/BIVI/
https://www.barchart.com/stocks/quotes/BIVI/overview
This from Market place Christmas eve .
Hedge Funds Weigh In On BioVie
A number of hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of BioVie during the second quarter valued at approximately $40,000. NewEdge Advisors LLC increased its position in shares of BioVie by 283.7% during the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock valued at $53,000 after purchasing an additional 40,000 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of BioVie during the 2nd quarter worth $57,000. Two Sigma Investments LP purchased a new position in shares of BioVie in the 3rd quarter worth about $62,000. Finally, Squarepoint Ops LLC bought a new position in BioVie during the third quarter valued at about $63,000. Hedge funds and other institutional investors own 4.59% of the company’s stock.
$ 1.540.00
Bought yesterday for 1.64 yesterday and 1.54 today .
Started: ripley94, 27 Oct 2025 14:08
Last post: ripley94, 1 hour ago
Https://www.google.com/finance/beta/quote/ACET:NASDAQ
Adicet Bio declined recently despite beating Q1 2026 earnings estimates. Major catalysts include upcoming mid-2026 clinical updates for prula-cel. Analysts project significant upside potential, though sentiment remains tempered by clinical trial risks and the necessity of future regulatory alignments for its autoimmune and solid tumor pipelines.
$ 8.46 +0.26 (+3.17%)
Sold back last top up for $8.5 target when I saw nearing it near target .
The first sale on this one , after 6 top ups .
5/2/26 first post consolidation Buy for 6.8p ( 25% lower )
$ 6.57-0.09 (-1.35%)
Pity I did not see this earlier 13th $7.26 .. 17th $7.19 above last top up .
https://www.nasdaq.com/market-activity/spos
Filings
12th March .
ACET Adicet Bio, Inc. 3/12/2026 $250,000,000
Share Price ..7.11+$0.22 (+3.09%)
Another that has not done well -33.99%
Broker has the Break-Even Price..$ 10.45 ( been consolidation maybe not correct )
5 top ups before 1 after consolidation .
Adicet Bio...$7.03 3pm
Maybe a live price.
Shows the $8.29 just after open , that broker had ( 15min delay )
https://robinhood.com/us/en/stocks/ACET/
Started: ripley94, 26 Sep 2025 16:55
Last post: ripley94, 1 hour ago
Https://www.google.com/finance/beta/quote/JSPR:NASDAQ
Jasper Therapeutics declined over the past month amid financing uncertainty. While positive clinical data for briquilimab in urticaria and asthma acted as a catalyst, recent analyst downgrades due to *capital concerns* have dampened sentiment. Market consensus suggests a volatile quarter as analysts project the company will prioritize securing funding for Phase 2b trials.
................................................................................
Recent Analyst Downgrades: Sentiment has weakened following a downgrade by TD Cowen from Buy to Hold in May 2026. Simultaneously, RBC Capital lowered its price target to $3.00, citing a 25% drop in expectations as the company faces execution hurdles and a potential "financial cliff."
$0.83935...-0.12...(-12.47%)
Big drop................. bought again 0.81.
Lots of spare cash on acc added to reason .
$ 0.8152....0.00 (-1.02% )
https://edition.cnn.com/markets/stocks/JSPR
Be interesting if this is up tomorrow .
Price change
The price of JSPR shares has increased $0.12 since the market last closed. This is a 16.48% rise.
What does this mean?
Investors are applying buying pressure to JSPR shares today.
$0.90..-0.15..(-14.28%)
Toped up for $0.88 executed on closing bell .
Slight mistake again with number ordered .
Might make that up if cheaper this week .
Share price $ 1.29-0.09(-6.52%)
Got the rest of yesterdays order for a cheaper $1.29 ( yesterdays 1.3 )
On new margin terms .
Using a lot of it today .
This the first of 12 USA buys to 7.30pm
Big falls again today USA tec -1.5% ( yesterday 2.5% )
The spos picks are proving to be very volatile .
RIP Margaret .
Started: ripley94, 9 Oct 2025 17:56
Last post: ripley94, 1 hour ago
Https://www.google.com/finance/beta/quote/HUMA:NASDAQ
Humacyte declined following a significant first-quarter revenue miss despite an earnings beat. Recent catalysts include a 25% workforce reduction and international expansion efforts. Analysts project a mixed next quarter, expecting increased product uptake for Symvess and critical Phase 3 trial data, though *liquidity concerns* persist through 2026.
$ 0.93
Bought again 0.91
Been a yo yo .
$0.6924..+0.04...(+7.28%)
Sold last traunch buy back for *0.69 ( *$0.6038 30th March )
Always just a trade .
Been a yo yo .
Paid $0.67 on 27th March ( had order on Friday 10th for 0.68 )
$0.5786...-0.09...(-14.35%)
Topped up again at *$0.6038
Still can not find details of fund rise last week .
Maybe saw as indication of 0.88
Topped up this Friday at $0.67 using margin .
Started: ripley94, 19 Oct 2025 13:06
Last post: ripley94, 1 hour ago
$2.28...+0.28...(+14.00%)
Sold Fridays top up back this Monday for 2.32.
Just a small profit , but beats the lost interest ( if the broker paid it ) on the spare cash over weekend by x20.
$ 5.730819 Bep.
https://www.google.com/finance/beta/quote/VNRX:NYSEAMERICAN
VolitionRX fell following a significant Q1 2026 earnings miss, despite a 300% revenue surge to approximately $1 million. Sentiment is weighed down by high cash burn and *going concern warnings*, though analysts project future growth contingent on unlocking a $5 million feline cancer test milestone and securing new licensing agreements.
Bought again at $2 .
https://robinhood.com/us/en/stocks/VNRX/
5/5/26 Buy 2.21
Adicet Bio Inc
0A4K
Early February picked up to 9th March then fell lower by 30th March below the split new price .
Consolidation
1for 16
3.15pm ..$2.63 ( 0.13 ) slightly cheaper .
Pre -Market $2.36 ( 0.118 )
1-for-20 reverse stock split,
https://robinhood.com/us/en/stocks/VNRX/
VolitionRX Limited
VNRX | US9286612067 new ticker .
VolitionRX Ltd Yesterdays ticker .
VNRX | US9286611077
$0.1361...0.00...(-2.85%)
Part of buy order executed at $0.13.5 this Monday ( 3 x as many as small amount of buy order executed at $0.16 last Monday )
0.13.5 x 20 equals $2.7 , Be interesting to see if matches that tomorrow .
Started: ripley94, 18 Sep 2025 17:02
Last post: ripley94, 4 May 2026
$ 11.40-0.37(-3.14%)
Topped up for $11.3 saw below target.
21/4/26 they were back up to $14.7 above the mid November slice price .
McGraw Hill Reports Higher Second Quarter Revenue and Digital Growth
There was a good RNs Yesterday hence the rise.
Same order did not lift yesterday .
The first buy now in profit .
Recent IPO 24/7/25 $17
Sliced last top up for $14.5.
Two weeks to the day ( Thursdays )
10.95 to 14.5 is approx 33 %
( Maybe on a role news was as good as could of expected )
30th October Topped up $10.95
Closed $10.84..-0.36..(-3.21%)
Guys concerning news
Topped up $10.95
Closed $10.84..-0.36..(-3.21%)
Guys concerning news.
Big fall today .
11.20...-1.15...-9.31%
https://uk.finance.yahoo.com/news/3-stocks-estimated-undervalued-48-173807928.html
After hours: 19:16:53 GMT-4
11.35..+0.15...+(1.34%)
Started: ripley94, 30 Oct 2025 19:51
Last post: ripley94, 7 Apr 2026
Close $ 6.95..+0.75..(+12.09%)
Sliced *$6.97... 14% above $6.1 target
Broker has Break-Even Price..$ 5.72
Share Price $ 5.745+0.53(+10.26%)
Top riser among these picks today .
On news.
Alpha Cognition Says USPTO Issues New U.S. Patent Covering ZUNVEYL Dosing Regimens.
Alpha Cognition Inc. said the U.S. Patent and Trademark Office has issued U.S. Patent Application No. 12,551,491, titled “Dosage Regimens for Benzgalantamine,” covering oral dosing regimens of benzgalantamine for treating mild to moderate Alzheimer’s disease. The company expects the patent to provide U.S. protection through July 2045 and to strengthen intellectual property around ZUNVEYL dosing methods.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602180830BIZWIRE_USPR_____20260218_BW956050) on February 18, 2026, and is solely responsible for the information contained therein.
Share Price $ 4.925-0.01(-0.30%)
Topped up again at *$4.93* Tb 5.2
They did get up to 6.6 on 30/12/25.
Had wanted to buy on last dip 15/12/25 at 5.3 but no funds to buy . ( up 10% next day )
Used brokers special loan arrangement .
As can close anytime and not at months end .
Bought today two times $6.25 target which was placing price , again 80 mins later at $6... 7.45pm
Just before this weeks early clocks back difference close ( USA 1.30pm to 8pm this week only )
1/10/25 Placing $6.25.
Vancouver Canada.
8/10/25 month high $7.72
https://www.marketbeat.com/stocks/NASDAQ/ACOG/
$18.00...186.17% Upside Just 1 analysts.
My broker shows the same.
https://www.barchart.com/stocks/quotes/ACOG/overview
Started: ripley94, 13 Oct 2025 15:51
Last post: ripley94, 22 Jan 2026
Share price $5.34..+0.49..(+10.10%)
Sold last top up back $ 5.25.
10 days after .
Bought again at $4.3.. on way to $4.15 day low.
Https://www.marketbeat.com/stocks/NASDAQ/IMRX/
Mixed reports here .
https://www.barchart.com/stocks/quotes/IMRX/overview
3rd Resistance Point 7.21
2nd Resistance Point 6.64
1st Resistance Point 5.69
Last Price 4.73
1st Support Level 4.17
2nd Support Level 3.60
3rd Support Level 2.6
Mixed news reports elsewhere online .
8 hours ago .. benzigna
Why Is Immuneering Stock Trading Lower Today? - Immuneering
9 hours ago ....TechStock²
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update
One day ago ...Investing.com UK
Immuneering stock falls after reporting survival data for pancreatic cancer drug.
Bought again at a lower $ 4.9 .
On way to Low $4.56
Rebought for $5.1 on $5.2 limit order strait through .
Down 38% today .
Immuneering stock falls after reporting survival data for pancreatic cancer drug.
Immuneering Corporation (NASDAQ:IMRX) stock fell 20% after hours Wednesday despite announcing positive survival data for its pancreatic cancer treatment, atebimetinib, in combination with modified gemcitabine/nab-paclitaxel (mGnP).
The company reported a 64% overall survival rate at 12 months for first-line pancreatic cancer patients treated with atebimetinib plus mGnP in its Phase 2a trial. This figure is nearly double the 35% benchmark from the pivotal study of standard care treatment. The median overall survival has not yet been reached after 13.4 months of median follow-up time.
Immuneering also reported strong surrogate endpoints, including a 39% confirmed overall response rate compared to the standard of care benchmark of 23%, and a disease control rate of 81% versus 48% for standard care. The median progression-free survival reached 8.5 months, compared to 5.5 months for the benchmark treatment.
"We are thrilled to report 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP," said Ben Zeskind, Ph.D., CEO of Immuneering. "The consistently strong separation observed between the overall survival in our clinical trial of atebimetinib in combination with mGnP in first-line pancreatic cancer patients and the benchmark for standard of care GnP from the MPACT study has now held at 6 months, 9 months, and 12 months."
Despite the positive data, investors appeared to react negatively to the announcement, possibly due to the company’s timeline for its pivotal Phase 3 trial, which is not expected to begin dosing patients until mid-2026.
Started: ripley94, 16 Sep 2025 21:43
Last post: ripley94, 13 Jan 2026
$2.005 now after topping out at $2.37 on 30th December 2025.
Achieve Life Sciences Inc the best of them at todays year high of $5.66 ( 22 September it was $3 )
Placed orders at $2.10 ..14th October after it fell back to the $3.
Started huge rise just after .
Fractyl Health ( GUTS )
Volatile
17/10/25 $1.29 +0.02 (+1.57%) on news.
After the rise and top out to 30th September too $ 1.5 .
Came back down to $1.25 16th October .
Was good idea last week .
Today Highest since the placing $ 1.1751+0.16 (+16.34%)
Https://www.nasdaq.com/market-activity/spos
Secondary Public Offerings (SPOs) USA
Also same time as Bionano Genomic.
ACTUATE THERAPEUTICS INC
Achieve Life Sciences Inc
Stock Markets
Published 08/06/2025, 10:50 AM ( 6th August )
Fractyl Health stock plunges after $20 million public offering
https://www.investing.com/news/stock-market-news/fractyl-health-stock-plunges-after-20-million-public-offering-93CH-4173828
Started: ripley94, 23 Oct 2025 19:37
Last post: ripley94, 23 Oct 2025
Https://www.marketbeat.com/stocks/NASDAQ/ACET/
https://www.barchart.com/stocks/quotes/ACET/overview
**Adicet Bio Receives Nasdaq Extension to Regain Compliance with Listing Requirements** Adicet Bio Inc. announced that it has received a notice from Nasdaq granting the company an additional 180-day extension, until April 6, 2026, to regain compliance with the minimum $1.00 per share bid price requirement for continued listing. As a result, Adicet's common stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective October 9, 2025. The company is considering options, including a possible reverse stock split, to address the deficiency. If Adicet does not meet the bid price requirement within the extension period, its shares may be subject to delisting, though the company would have the right to appeal.
Started: ripley94, 19 Oct 2025 11:07
Last post: ripley94, 20 Oct 2025
Today up 19% to $5
16/9/25 order on
21/8/25 H.C. Wainwright initiates coverage with buy rating price then $2.89 ?
26/6/25 placing $3 with warrants @ $3
Achieve Life Sciences ( ACHV )
17/10/25 $4.20 +1.12 (+36.36%)
On news Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
https://www.barchart.com/stocks/quotes/ACHV/overview
https://www.marketbeat.com/stocks/NASDAQ/ACHV/
One of the first 3 I looked at .
17/10/25 up 40%
Usually rejected after 2/10/25 but did place order on 14/10/25
Https://www.nasdaq.com/market-activity/spos
Secondary Public Offerings (SPOs) USA
Also same time as Bionano Genomic.
Others
ACTUATE THERAPEUTICS INC
Fractyl Health ( noted on thread 20th September ) Also big gain on 16/10/25.
Started: ripley94, 17 Feb 2022 23:10
Last post: ripley94, 10 May 2022
Topped up yesterday did not notice price feed was live* and it was lower then days low at moment I placed deal so flew strait threw at $1.39 first batch then 2 parts at 1.38 . First buy in USA tumbling markets 4.22pm .
The 3 parts less then the 10 last time .
But yesterday day Mereo went through in 18 parts .
This showing no change in price today .
This was the first buy of very busy day 11 USA buys ( placed 33 orders )
Bought that sold tranche back for $2.05 , went through in 10 parts .
always the order executes in bits ( 2 and 7 before )
Started: ripley94, 13 Feb 2022 18:05
Last post: ripley94, 13 Feb 2022
Just original buy left now .
Started: Oliverjack7, 28 Jan 2021 10:20
Last post: Oliverjack7, 28 Jan 2021
Why is no one talking about these shares?
Started: Oliverjack7, 28 Jan 2021 10:19
Last post: Oliverjack7, 28 Jan 2021
Why is no one talking about this ?!
Started: wozzer70, 9 Oct 2020 18:49
Last post: Everton222, 4 Jan 2021
Nice rise. Even those in on open have benefitted.
They have their 4 day symposium starting on the 11th of January. It will be interesting to hear more about the technology. I find it difficult to answer your £4 question, who knows what might happen pre market on Monday.
wozzer 70
you seem to be the only man on this board do think an entry price of $4 on monday
is ok
Started: wozzer70, 8 Oct 2020 20:41
Last post: wozzer70, 8 Oct 2020
Started: wozzer70, 2 Oct 2020 15:50
Last post: wozzer70, 2 Oct 2020
Started: wozzer70, 2 Oct 2020 15:37
Last post: wozzer70, 2 Oct 2020
Updates due very soon before this takes off.
All looking very positive for bionano. Plenty of info out there if your researching.
Started: wozzer70, 2 Oct 2020 07:39
Last post: wozzer70, 2 Oct 2020
Started: wozzer70, 2 Oct 2020 07:35
Last post: wozzer70, 2 Oct 2020
Selected partners may offer promotions for new customers. We may earn a referral fee if you open an account
Follow the stocks
that matter to you
Create a free LSE account to:
Already a member? Log in
Create Free Account

